These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32505632)

  • 1. Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors.
    Li XY; Zhu XR; Zhang CC; Yu W; Zhang B; Shen TL; Zhang HY; Fu XL
    Clin Lung Cancer; 2020 Nov; 21(6):534-544. PubMed ID: 32505632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.
    Mizuno T; Horinouchi H; Watanabe S; Sato J; Morita R; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2020 Apr; 11(4):1038-1044. PubMed ID: 32077630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
    Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India.
    Garg A; Batra U; Choudhary P; Jain D; Khurana S; Malik PS; Muthu V; Prasad KT; Singh N; Suri T; Mohan A
    Curr Probl Cancer; 2020 Jun; 44(3):100570. PubMed ID: 32498966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
    BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of mean platelet volume (MPV), MPV/PLATELET (PLT) ratio, and lymphocyte/monocyte ratio (LMR) as poor prognostic factor in EGFR-mutant lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor.
    Kurt HG; Akinci Özyürek B; Erdoğan Y; Akyürek N
    Tuberk Toraks; 2024 Sep; 72(3):197-207. PubMed ID: 39275932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
    Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
    Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
    Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia.
    Widiasari NPA; Rai IBN; Dwi Kusumawardani IAJ; Sajinadiyasa IGK; Candrawati NW; Arisanti NLPE
    Rom J Intern Med; 2023 Mar; 61(1):63-71. PubMed ID: 36453446
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy.
    Shen CI; Huang HC; Chiang CL; Luo YH; Shiao TH; Chiu CH
    Lung Cancer; 2019 Dec; 138():52-57. PubMed ID: 31634655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the prognostic value of the new 9th edition Tumor-Node-Metastases (TNM) staging system for epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients with bone metastases.
    Peng J; Hu F; Mao X; Niu Y; Ma M; Jiang L
    BMC Pulm Med; 2024 Oct; 24(1):508. PubMed ID: 39394157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment.
    Hung HY; Tseng YH; Liao CM; Chen SY; Wu TP; Lee YC; Chen YM
    Integr Cancer Ther; 2017 Mar; 16(1):126-131. PubMed ID: 27151582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI.
    Tang Y; Xia B; Xie R; Xu X; Zhang M; Wu K; Wang B; Ma S
    Lung Cancer; 2020 Feb; 140():65-70. PubMed ID: 31884128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs.
    Jiang J; Gu Y; Liu J; Wu R; Fu L; Zhao J; Guan Y
    Lung Cancer; 2016 Dec; 102():101-107. PubMed ID: 27987577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of SIRI in patients with late-stage lung adenocarcinoma receiving EGFR-TKI treatment.
    Wang H; Li W
    Curr Probl Cancer; 2024 Jun; 50():101099. PubMed ID: 38723294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
    Hong SH; Kim YS; Lee JE; Kim IH; Kim SJ; Han D; Yoo IeR; Chung YG; Kim YH; Lee KY; Kang JH
    Cancer Res Treat; 2016 Jul; 48(3):1110-9. PubMed ID: 26790969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
    Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J
    Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
    Hu F; Xu J; Zhang B; Li C; Nie W; Gu P; Hu P; Wang H; Zhang Y; Shen Y; Wang S; Zhang X
    Clin Lung Cancer; 2019 Jan; 20(1):e81-e90. PubMed ID: 30341018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.